Climb Bio is a clinical-stage biotechnology company focused on developing therapies for immune-mediated diseases. Its pipeline includes antibody-based candidates intended to address B-cell-driven disorders and related conditions.
No data available
Are you interested in the impact of this company or this ETF?
It seems we haven't collected any data here yet. Just let us know and we will try to find data as soon as possible. Thank you for your feedback!